Management of obsessive-compulsive disorder with fluvoxamine extended release

L&iacute;dia Ordacgi1, Mauro V Mendlowicz2, Leonardo F Fontenelle11Anxiety and Depression Research Program, Institute of Psychiatry, Universidade Federal do Rio de Janeiro (IPUB/UFRJ), Rio de Janeiro, Brazil; 2Department of Psychiatry and Mental Health, Universidade Federal Fluminense (MSM-U...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	L&iacute;dia Ordacgi, Mauro V Mendlowicz, Leonardo F Fontenelle
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c830afc5584e40ed8896e5b09818c0cd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c830afc5584e40ed8896e5b09818c0cd
record_format	dspace
spelling	oai:doaj.org-article:c830afc5584e40ed8896e5b09818c0cd2021-12-02T07:57:32ZManagement of obsessive-compulsive disorder with fluvoxamine extended release1176-63281178-2021https://doaj.org/article/c830afc5584e40ed8896e5b09818c0cd2009-05-01T00:00:00Zhttp://www.dovepress.com/management-of-obsessive-compulsive-disorder-with-fluvoxamine-extended--a3167https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021L&iacute;dia Ordacgi1, Mauro V Mendlowicz2, Leonardo F Fontenelle11Anxiety and Depression Research Program, Institute of Psychiatry, Universidade Federal do Rio de Janeiro (IPUB/UFRJ), Rio de Janeiro, Brazil; 2Department of Psychiatry and Mental Health, Universidade Federal Fluminense (MSM-UFF), Niter&oacute;i, BrazilAbstract: The pharmacodynamic properties of fluvoxamine maleate include the modulation of different populations of serotonergic, dopaminergic, and sigma receptors and/or transporters, a complex pattern of activity that may account for its efficacy in the treatment of obsessive-compulsive disorder (OCD). Nevertheless, its pharmacokinetic profile and its pattern of side effects may hinder a rapid dose escalation, a therapeutic strategy that might be utterly desirable in patients with OCD. In preclinical studies, the maximum plasma concentration and bioavailability of an extended-release (CR) formulation of fluvoxamine were, respectively, 38% and 16% lower than those of the standard (ie, non-CR) formulation. Recently, the US Food and Drug Administration approved the fluvoxamine CR formulation for the treatment of OCD in adults. This approval was based on the results of a double-blind, placebo-controlled study with 253 OCD patients in which fluvoxamine CR showed a consistently earlier onset of therapeutic effects than other selective serotonin reuptake inhibitors, as reported in previous studies. The use of the CR formulation of fluvoxamine allowed a particularly aggressive dosing strategy at the beginning of the titration phase, ie, treatment could be started with a single dose of fluvoxamine CR 100 mg at bedtime, while keeping the occurrence of side effects and the rate of compliance at levels comparable to those reported for the use of immediate-release fluvoxamine.Keywords: obsessive-compulsive disorder, fluvoxamine, fluvoxamine extended release L&iacute;dia OrdacgiMauro V MendlowiczLeonardo F FontenelleDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 301-308 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 L&iacute;dia Ordacgi Mauro V Mendlowicz Leonardo F Fontenelle Management of obsessive-compulsive disorder with fluvoxamine extended release
description	L&iacute;dia Ordacgi1, Mauro V Mendlowicz2, Leonardo F Fontenelle11Anxiety and Depression Research Program, Institute of Psychiatry, Universidade Federal do Rio de Janeiro (IPUB/UFRJ), Rio de Janeiro, Brazil; 2Department of Psychiatry and Mental Health, Universidade Federal Fluminense (MSM-UFF), Niter&oacute;i, BrazilAbstract: The pharmacodynamic properties of fluvoxamine maleate include the modulation of different populations of serotonergic, dopaminergic, and sigma receptors and/or transporters, a complex pattern of activity that may account for its efficacy in the treatment of obsessive-compulsive disorder (OCD). Nevertheless, its pharmacokinetic profile and its pattern of side effects may hinder a rapid dose escalation, a therapeutic strategy that might be utterly desirable in patients with OCD. In preclinical studies, the maximum plasma concentration and bioavailability of an extended-release (CR) formulation of fluvoxamine were, respectively, 38% and 16% lower than those of the standard (ie, non-CR) formulation. Recently, the US Food and Drug Administration approved the fluvoxamine CR formulation for the treatment of OCD in adults. This approval was based on the results of a double-blind, placebo-controlled study with 253 OCD patients in which fluvoxamine CR showed a consistently earlier onset of therapeutic effects than other selective serotonin reuptake inhibitors, as reported in previous studies. The use of the CR formulation of fluvoxamine allowed a particularly aggressive dosing strategy at the beginning of the titration phase, ie, treatment could be started with a single dose of fluvoxamine CR 100 mg at bedtime, while keeping the occurrence of side effects and the rate of compliance at levels comparable to those reported for the use of immediate-release fluvoxamine.Keywords: obsessive-compulsive disorder, fluvoxamine, fluvoxamine extended release
format	article
author	L&iacute;dia Ordacgi Mauro V Mendlowicz Leonardo F Fontenelle
author_facet	L&iacute;dia Ordacgi Mauro V Mendlowicz Leonardo F Fontenelle
author_sort	L&iacute;dia Ordacgi
title	Management of obsessive-compulsive disorder with fluvoxamine extended release
title_short	Management of obsessive-compulsive disorder with fluvoxamine extended release
title_full	Management of obsessive-compulsive disorder with fluvoxamine extended release
title_fullStr	Management of obsessive-compulsive disorder with fluvoxamine extended release
title_full_unstemmed	Management of obsessive-compulsive disorder with fluvoxamine extended release
title_sort	management of obsessive-compulsive disorder with fluvoxamine extended release
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/c830afc5584e40ed8896e5b09818c0cd
work_keys_str_mv	AT lampiacutediaordacgi managementofobsessivecompulsivedisorderwithfluvoxamineextendedrelease AT maurovmendlowicz managementofobsessivecompulsivedisorderwithfluvoxamineextendedrelease AT leonardoffontenelle managementofobsessivecompulsivedisorderwithfluvoxamineextendedrelease
_version_	1718399067150614528

Management of obsessive-compulsive disorder with fluvoxamine extended release

Ejemplares similares